Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The blood-brain barrier (BBB) is an intricate barrier composed of a variety of efflux pumps,
a luminal negative charge, a basal lamina and three distinct cell types: brain endothelial
cells, pericytes, and astrocyte foot processes. Specifically, the BBB integrity and degree of
permeability is regulated by the capillary endothelial cells in response to astrocytic
signals. The strength of intercellular junctions (ex. tight junctions, adherins) amongst
endothelial cells also plays a major role in permeability. Therefore, modulation of all these
paracellular properties may decrease BBB integrity and thus improve drug penetration to the
tumor bed. Previous studies utilizing the vasoactive peptide, Regadenoson, demonstrated
transient increase in BBB permeability, allowing a 70kD dextran molecule to enter the brain
of rodents. Thus, the investigators propose to evaluate brain interstitium concentrations of
temozolomide pre and post Regadenoson using brain microdialysis. If Regadenoson successfully
demonstrates effectiveness in disrupting the BBB, it could be of major importance in
improving the outcome of patients with a variety of brain tumors and other neurologic
illnesses.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins